CliffBio
biologic

Balfaxar

Prothrombin complex concentrate, human-lans

Loss of exclusivityJuly 2035projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand nameBalfaxar
Active ingredientProthrombin complex concentrate, human-lans
Strength500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2023
Marketing statusRx

More from Octapharma Pharmazeutika Produktionsges.m.b.H.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found